Proteins encoded by the c-myc oncogene: analysis of c-myc protein degradation. 1986

B Lüscher, and R N Eisenman
Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.

We have examined one of the most striking characteristics of the c-myc oncogene protein product: its extremely short half-life relative to all but a few normal cellular proteins. Our studies indicate that the rapid degradation of c-myc proteins is not confined to human and avian cells, where it was first observed, but is found in cells derived from as evolutionarily widely separated species as murine and amphibian as well as in both normal and transformed cells. In addition the rate of degradation appears to be essentially the same throughout the G1, S, and G2 phases of the cell cycle as determined by "pulse-chase" analysis of cell cycle subpopulations separated by centrifugal elutriation. Kinetic analysis of c-myc protein turnover utilizing immunoprecipitation from labelled cells or immunoblotting of total nuclei indicate that there is not likely to be a significantly large pool of the protein which is protected from degradation and that no major degradation products can be detected. Evidence that the nucleus plays a role in degradation comes from preliminary experiments which indicate that in enucleated cells the c-myc proteins are stable. We also discuss evidence suggesting that myc proteins are stable in mitotic cells. Finally, using a series of chemical agents we have found conditions which inhibit in vivo degradation. These experiments indicate the involvement of both ATP and metal ions in degradation of c-myc proteins.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011519 Proto-Oncogenes Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc. Proto-Oncogene,Proto Oncogene,Proto Oncogenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016271 Proto-Oncogene Proteins c-myc Basic helix-loop-helix transcription factors encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis. L-myc Proteins,N-myc Proteins,c-myc Proteins,myc Proto-Oncogene Proteins,p62(c-myc),Proto-Oncogene Products c-myc,Proto-Oncogene Proteins myc,myc Proto-Oncogene Product p62,p62 c-myc,L myc Proteins,N myc Proteins,Proteins myc, Proto-Oncogene,Proto Oncogene Products c myc,Proto Oncogene Proteins c myc,Proto Oncogene Proteins myc,Proto-Oncogene Proteins, myc,c myc Proteins,myc Proto Oncogene Product p62,myc Proto Oncogene Proteins,myc, Proto-Oncogene Proteins,p62 c myc

Related Publications

B Lüscher, and R N Eisenman
December 1984, Proceedings of the National Academy of Sciences of the United States of America,
B Lüscher, and R N Eisenman
November 1984, Molecular and cellular biology,
B Lüscher, and R N Eisenman
May 1986, Science (New York, N.Y.),
B Lüscher, and R N Eisenman
November 1989, Oncogene,
B Lüscher, and R N Eisenman
September 2004, Oncogene,
B Lüscher, and R N Eisenman
October 2001, Nihon rinsho. Japanese journal of clinical medicine,
B Lüscher, and R N Eisenman
November 1986, Molecular and cellular biology,
B Lüscher, and R N Eisenman
January 1985, Molecular and cellular biology,
B Lüscher, and R N Eisenman
October 1985, Proceedings of the Royal Society of London. Series B, Biological sciences,
B Lüscher, and R N Eisenman
January 1986, Basic life sciences,
Copied contents to your clipboard!